• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2013 - Product Image

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2013

  • ID: 2557598
  • May 2013
  • 34 pages
  • Global Markets Direct

Chemotherapy Induced Myelosuppression – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Myelosuppression. Chemotherapy Induced Myelosuppression - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Myelosuppression.
- READ MORE >

Note: Product cover images may vary from those shown

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chemotherapy Induced Myelosuppression Overview
Therapeutics Development
An Overview of Pipeline Products for Chemotherapy Induced Myelosuppression
Chemotherapy Induced Myelosuppression Therapeutics under Development by Companies
Chemotherapy Induced Myelosuppression Therapeutics under Investigation by Universities/Institutes
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Chemotherapy Induced Myelosuppression Therapeutics – Products under Development by Companies
Chemotherapy Induced Myelosuppression Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chemotherapy Induced Myelosuppression Therapeutics Development
Pharmagenesis, Inc.
Biothera
Chemotherapy Induced Myelosuppression – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PGG beta-glucan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dinoprostone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PG2-2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHIP1 Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AstraStim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Myelosuppression Therapeutics – Drug Profile Updates
Chemotherapy Induced Myelosuppression Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Chemotherapy Induced Myelosuppression, H1 2013
Products under Development for Chemotherapy Induced Myelosuppression – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Pharmagenesis, Inc., H1 2013
Biothera, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Chemotherapy Induced Myelosuppression Therapeutics – Drug Profile Updates
Chemotherapy Induced Myelosuppression Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2013
Products under Development for Chemotherapy Induced Myelosuppression – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 21

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos